Stoke Therapeutics (NASDAQ:STOK) Trading Up 3.4% – Should You Buy?

Stoke Therapeutics, Inc. (NASDAQ:STOK) shares traded up 3.4% on Tuesday . The stock traded as high as $11.79 and last traded at $11.79. 12,601 shares traded hands during trading, a decline of 98% from the average session volume of 794,577 shares. The stock had previously closed at $11.40.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on STOK shares. HC Wainwright restated a “buy” rating and issued a $35.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, September 11th. Needham & Company LLC restated a “buy” rating and set a $22.00 price target on shares of Stoke Therapeutics in a report on Thursday, August 8th. Finally, Wedbush reaffirmed an “outperform” rating and set a $17.00 price target on shares of Stoke Therapeutics in a research report on Thursday, July 11th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $21.40.

Stoke Therapeutics Price Performance

The business’s 50 day moving average price is $14.02 and its 200 day moving average price is $13.65. The stock has a market capitalization of $642.65 million, a P/E ratio of -5.13 and a beta of 0.97.

Stoke Therapeutics (NASDAQ:STOK) last announced its earnings results on Wednesday, August 7th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.11. Stoke Therapeutics had a negative return on equity of 57.89% and a negative net margin of 683.35%. The business had revenue of $4.83 million for the quarter, compared to analysts’ expectations of $3.33 million. As a group, analysts forecast that Stoke Therapeutics, Inc. will post -2.1 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, major shareholder Skorpios Trust sold 1,937,500 shares of the company’s stock in a transaction on Thursday, September 19th. The stock was sold at an average price of $14.05, for a total value of $27,221,875.00. Following the completion of the sale, the insider now directly owns 8,906,181 shares in the company, valued at $125,131,843.05. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. 11.30% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Nisa Investment Advisors LLC lifted its holdings in Stoke Therapeutics by 53.2% during the second quarter. Nisa Investment Advisors LLC now owns 2,989 shares of the company’s stock valued at $40,000 after purchasing an additional 1,038 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Stoke Therapeutics by 5.5% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 31,431 shares of the company’s stock worth $425,000 after buying an additional 1,642 shares during the period. The Manufacturers Life Insurance Company increased its stake in Stoke Therapeutics by 16.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company’s stock worth $189,000 after buying an additional 1,994 shares in the last quarter. Quest Partners LLC bought a new stake in Stoke Therapeutics during the second quarter valued at about $29,000. Finally, Los Angeles Capital Management LLC raised its holdings in Stoke Therapeutics by 7.2% during the second quarter. Los Angeles Capital Management LLC now owns 66,765 shares of the company’s stock valued at $902,000 after acquiring an additional 4,508 shares during the period.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.